Manejo del paciente | 17 OCT 07
Hipertiroidismo subclínico
Solo la realización de trabajos prospectivos aleatorizados podrá responder cuál es el mejor manejo de este problema clínico tan importante.
Autor/a: Dr. David S. Cooper J Clin Endocrinol Metab 92: 3–9, 2007
Desarrollo
1. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE 2002 Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 87:489–499
2. Laurberg P, Pedersen KM, Hreidarsson A, Sigfusson N, Iversen E, Knudsen PR 1998 Iodine intake and the pattern of thyroid disorders: a comparative epidemiological study of thyroid abnormalities in the elderly in Iceland and in Jutland, Denmark. J Clin Endocrinol Metab 83:765–769
3. Belfiore A, Sava L, Runello F, Tomaselli L, Vigneri R 1996 Solitary autonomously functioning thyroid nodules and iodine deficiency. J Clin Endocrinol Metab 56:283–287
4. Lewis GF, Alessi CA, Imperial JG, Refetoff S 1991 Low serum free thyroxine index in ambulating elderly is due to a resetting of the threshold of thyrotropin feedback suppression. J Clin Endocrinol Metab 73:843–849
5. Mariotti S, Barbesino G, Caturegli P, Bartalena L, Sansoni P, Fagnoni F, Monti D, Fagiolo U, Franceschi C, Pinchera A 1993 Complex alteration of thyroid function in healthy centenarians J Clin Endocrinol Metab 77:1130–1134
6. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ 2004 Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 291:228–238
7. Biondi B, Palmieri EA, Klain M, Schlumberger M, Filetti S, LombardiG2005 Subclinical hyperthyroidism: clinical features and treatment options. Eur J Endocrinol 152:1–9
8. Papi G, Pearce EN, Braverman LE, Betterle C, Roti E 2005 A clinical and therapeutic approach to thyrotoxicosis with thyroid-stimulating hormone suppression only. Am J Med 118:349–361
9. Klein I, Ojamaa K 2001 Thyroid hormone and the cardiovascular system. N Engl J Med 344:501–509
10. Petretta M, Bonaduce D, Spinelli L, Vicario MLE, Nuzzo V, Marciano F, Camuso P, De Sanctis V, Lupoli G 2001 Cardiovascular haemodynamics and cardiac autonomic control in patients with subclinical and overt hyperthyroidism. Eur J Endocrinol 145:691–696
11. Biondi B, Palmieri EA, Fazio S, Cosco C, Nocera M, Sacca` L, Filetti S, Lombardi G, Perticone F 2000 Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middleaged patients. J Clin Endocrinol Metab 85:4701–4705
12. Sgarbi JA, Villaca F, Garbeline B, Villar HE, Romaldini JH 2003 The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism on clinical and heart abnormalities. J Clin Endocrinol Metab 88:1672–1677
13. Kannel WB, Cobb J 1992 Left ventricular hypertrophy and mortality–results from the Framingham Study. Cardiology 81:291–298
14. Tamer I, Sargin M, Sargin H, Seker M, Babalik E, Tekce M, Yayla A 2005 The evaluation of left ventricular hypertrophy in hypertensive patients with subclinical hyperthyroidism. Endocr J 52:421–425
15. Dorr M, Wolff B, Robinson DM, John U, Ludemann J, Meng W, Felix SB, Volzke H 2005 The association of thyroid function with cardiac mass and left ventricular hypertrophy. J Clin Endocrinol Metab 90:673–677
16. Yavuz H, Altunbas H, Balci MK, Demirciogˇ lu F, C¸ akir M, Karayalc¸inU¨ 2000 Normal systolic time intervals in subclinical hyperthyroidism. J Endocrinol Invest 23:38 (Abstract)
17. Biondi B, Fazio S, Cuocolo A, Sabatini D, Nicolai E, Lombardi G, Salvatore M, Sacca L 1996 Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine. J Clin Endocrinol Metab 81:4224–4228
18. Mercuro G, Panzuto MG, Bina A, Leo M, Cabula R, Petrini L, Pigliaru F, Mariotti S 2000 Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring. J Clin Endocrinol Metab 85:159–164
19. Tenerz A, Forberg R, Jansson R 1990 Is a more active attitude warranted in patients with subclinical thyrotoxicosis? J Intern Med 228:229–233
20. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wilson PW, Benjamin EJ, D’Agostino RB 1994 Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 331:1249–1252
21. Auer JA, Scheibner P, Mische T, Langsteger W, Eber O, Eber B 2001 Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J 142:838–842
22. Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, Tracy RP, Ladenson PW 2006 Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 295:1033–1041
23. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA 2001 Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 358:861–865
24. Gussekloo J, van Exel E, de Craen AJ, Meinders AE, Frolich M, Westendorp RG 2004 Thyroid status, disability and cognitive function, and survival in old age. JAMA 292:2591–2599
25. Walsh JP, Bremner AP, Bulsara MK, O’Le
Comentarios
Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024